These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 30076703)

  • 1. Estrogen-related receptor γ negatively regulates osteoclastogenesis and protects against inflammatory bone loss.
    Kim HJ; Kim BK; Ohk B; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR
    J Cell Physiol; 2019 Feb; 234(2):1659-1670. PubMed ID: 30076703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways.
    Park JW; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR; Kim HJ
    J Cell Physiol; 2018 Feb; 233(2):1481-1489. PubMed ID: 28574596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo.
    Han B; Geng H; Liu L; Wu Z; Wang Y
    Biomed Pharmacother; 2020 Aug; 128():110305. PubMed ID: 32485573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
    Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
    Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional Modulator Ifrd1 Regulates Osteoclast Differentiation through Enhancing the NF-κB/NFATc1 Pathway.
    Iezaki T; Fukasawa K; Park G; Horie T; Kanayama T; Ozaki K; Onishi Y; Takahata Y; Nakamura Y; Takarada T; Yoneda Y; Nakamura T; Vacher J; Hinoi E
    Mol Cell Biol; 2016 Oct; 36(19):2451-63. PubMed ID: 27381458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
    Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
    Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
    Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
    PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
    Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
    Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
    Song J; Jing Z; Hu W; Yu J; Cui X
    Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The estrogen-related receptor γ modulator, GSK5182, inhibits osteoclast differentiation and accelerates osteoclast apoptosis.
    Kim HJ; Yoon HJ; Lee DK; Jin X; Che X; Choi JY
    BMB Rep; 2021 May; 54(5):266-271. PubMed ID: 33612148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
    Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
    BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.